Share This Page
Drugs in ATC Class J01XE
✉ Email this page to a colleague
Drugs in ATC Class: J01XE - Nitrofuran derivatives
| Tradename | Generic Name |
|---|---|
| NITROFURANTOIN | nitrofurantoin |
| FURADANTIN | nitrofurantoin |
| FURALAN | nitrofurantoin |
| IVADANTIN | nitrofurantoin sodium |
| MACRODANTIN | nitrofurantoin, macrocrystalline |
| NITROFURANTOIN | nitrofurantoin, macrocrystalline |
| >Tradename | >Generic Name |
Market dynamics and patent landscape for ATC Class J01XE (nitrofuran derivatives): what protections exist and where generics face risk
ATC Class J01XE (nitrofuran derivatives) is a small, compliance-driven antibiotic segment with limited platform-like patent estates and a pattern of older, expiring composition-of-matter protections plus narrower, formulation, polymorph, salt, and manufacturing patents. Market dynamics skew toward (1) long-lived off-patent molecules used for specific indications, (2) constrained supply and quality issues in some markets, and (3) product-specific exclusivities (where applicable) that delay full generic substitution even after API patents expire.
Patent friction is generally not in “new chemistry” but in product-level IP: process improvements, solid-state forms, bioavailability-enhancing formulations, and line-by-line regulatory/CMC data exclusivity. For investors and litigators, the most relevant exercise is mapping each marketed nitrofuran derivative by product form (capsule/tablet/suspension), the Orange Book status in the US, and jurisdictional patent filings covering formulation and manufacturing steps.
Which nitrofuran derivatives are in ATC J01XE, and what’s driving demand by indication?
Featured snippet answer: J01XE is a nitrofuran class that is used across urinary and other bacterial indications, with demand driven more by prescriber preference, local formularies, tolerability, and supply reliability than by rapid label expansion.
Common marketed nitrofuran derivatives that typically map to J01XE
J01XE is widely used as a classification label in drug reference databases for nitrofuran derivatives. In practice, the segment’s commercial “center of gravity” is usually:
- Nitrofurantoin (oral urinary tract indications; multiple formulations and strengths historically)
- Nitrofurazone (topical/dermal use in some jurisdictions; not always treated as a “systemic antibiotic” revenue engine)
- Furazolidone / related nitrofurans (availability varies by country and regulatory history)
Because J01XE is a class-level bucket, market dynamics differ by molecule. The most investable “market” is usually nitrofurantoin because it has broad outpatient use and many branded/generic SKUs globally.
What drives market share inside nitrofuran derivatives?
- Indication fit and guideline placement: Nitrofurantoin use correlates with uncomplicated cystitis guideline adherence in specific health systems.
- Safety and monitoring constraints: Renal function thresholds and adverse event profiles influence substitution decisions and payer controls.
- Formulary behavior: Older antibiotics often face restricted formulary controls that can slow generic switching even when patents end.
- Supply continuity: Nitrofurantoin is sensitive to manufacturing and quality system capacity, which can create temporary pricing power for active, compliant suppliers.
How does the patent landscape for nitrofuran derivatives typically look (composition vs formulation vs process patents)?
Featured snippet answer: For J01XE, patent estates skew toward late-stage product patents (formulation, polymorph/solid-state, process) rather than broad composition-of-matter covering modern product forms for long periods.
Typical patent estate structure for older nitrofurans
- Early composition-of-matter and/or intermediates patents
- For molecules in current use, these often expire decades after first filing.
- Solid-state and particle engineering patents
- Polymorphs, hydrates, solvates, particle size distributions, and controlled-release matrices.
- Formulation patents
- Capsules/tablets with specific excipient systems, coated versions, and improved dissolution profiles.
- Manufacturing method patents
- Specific synthesis steps, purification/recrystallization conditions, and scale-up controls that improve yield or stability.
- Regulatory exclusivity layered on top of patents
- In the US, Orange Book “30-month stay” dynamics and exclusivity periods can matter even when core composition IP has lapsed.
Practical consequence for competition
Even where API patents are expired, product-level IP and CMC data packages can delay entry, especially for:
- modified-release products
- higher-bioavailability formulations
- specific strength/product presentations with entrenched clinician use
When does nitrofurantoin lose exclusivity in key jurisdictions, and what does that imply for generic timing?
Featured snippet answer: Most nitrofuran derivatives in routine use are already beyond primary composition-of-matter exclusivity in major markets; the entry calendar is therefore driven by residual formulation/process patents and by regulatory/Orange Book listings tied to each specific marketed presentation.
What “loss of exclusivity” means in practice
- Primary composition expiry usually removes the main legal barrier to generics.
- Residual patent barriers delay entry for a particular SKU:
- formulation-specific patents
- method-of-manufacture patents
- specific polymorph claims
- Regulatory exclusivity can still prevent approval or can create a pricing/launch runway for authorized generics.
Generic entry scenario (typical for older nitrofuran SKUs)
- If the product has no listed, unexpired patents in the relevant jurisdiction, Paragraph IV or non-infringing pathways can lead to straightforward approvals and rapid price erosion.
- If formulation or process patents remain listed and are asserted, generic launch can be delayed by:
- litigation injunction risks
- settlement agreements that include delayed effective dates
- product launch design changes (e.g., different polymorph selection) that avoid infringement
What patents protect nitrofuran derivatives formulations (capsules, tablets, suspensions), and how many families typically remain active?
Featured snippet answer: Active patents, when they exist, are usually concentrated in a limited number of families per marketed presentation covering polymorph/solid-state, dissolution, and manufacturing conditions. The number is often smaller than investors expect in older antibiotic segments.
Formulation and solid-state targets that recur in filings
- polymorph/hydrate/solvate states
- controlled particle size and distribution
- coating and dissolution modifiers
- stability windows and moisture control
- bioavailability-related formulation architecture
- protective film systems for taste and GI tolerability
Manufacturing IP that can block “drop-in” substitution
- synthesis route parameters that change impurity profiles
- recrystallization and drying conditions
- scale-up and mixing controls that can be claim-protected
- quality system linked manufacturing steps (rarely broad but can be litigated)
How to read this for competitive strategy
- If the commercial need is “fast entry,” generic programs focus on whether a single presentation’s listed patents cover the manufacturing route or the selected solid form.
- If the commercial need is “defensible market share,” branded holders concentrate on keeping a small but targeted set of patents active around their specific SKU configuration.
What Orange Book status patterns exist for nitrofurantoin products, and how does that change Paragraph IV risk?
Featured snippet answer: Orange Book status typically turns the risk into a product-by-product exercise. Even with expired API patents, the listed patent set for a specific presentation can dictate whether a generic can launch immediately or needs to design around solid-state/formulation claims.
Paragraph IV risk mechanics in this class
- Many nitrofuran generic applicants file ANDAs referencing a listed brand presentation.
- The existence of any unexpired listed patents covering formulation or manufacturing can drive:
- Paragraph IV certifications (carve-out strategy)
- litigation with 30-month stays in the US
- settlement agreements that delay launch
How this affects infringement exposure
- Composition-only claims that are expired reduce risk substantially.
- Active formulation/process claims can create substantial risk if the generic cannot demonstrate non-infringement or invalidity.
What patent litigation affects nitrofuran derivatives, and what settlement terms usually determine launch dates?
Featured snippet answer: Litigation in older antibiotic segments often resolves with settlement-driven launch date controls rather than long-running merits trials, with the most enforceable terms tied to US launch timing and non-design-around covenants.
Typical settlement levers seen in practice
- delayed effective launch date
- stipulations on infringement positions
- covenant not to sell until a specific date
- limitation to certain strengths or dosage forms
- “design-around” acceptability for generic reformulation
Why this matters for J01XE
- The class’s value is per-SKU, not per-molecule. A settlement can preserve share for a branded presentation even if other strengths/products are already generic.
- Litigation can also influence subsequent regulatory approvals by shaping the evidentiary record and design-around feasibility.
How strong is the patent estate for nitrofuran derivatives compared with other antibiotic classes?
Featured snippet answer: Patent strength in J01XE tends to be narrower and more presentation-specific than in recent antibiotic classes with platform chemistry or long-lived biologic-like estates.
Comparative positioning
- Against newer small-molecule antibiotics: J01XE usually has fewer “deep” remaining composition-of-matter families.
- Against complex dosage forms: J01XE is less likely to have extensive drug-device or multi-component systems.
- Against biologics/large molecules: J01XE is structurally simpler, which limits the number of patent hooks available beyond formulation and process.
What this means for ROI
- High ROI niches exist where:
- a premium formulation is protected by active formulation patents
- a specific solid state is claim-protected
- there is a supply constraint that amplifies pricing during exclusivity gaps
Which companies compete in nitrofuran derivatives, and where are generic entry opportunities strongest?
Featured snippet answer: Competition is usually dominated by established generics for off-patent presentations, while branded holders or authorized generics retain limited share where product-level IP or supply constraints persist.
Generic entry opportunities (where risk is lowest)
- presentations with no unexpired listed patents
- strengths where the reference product’s active patents have expired
- dosage forms where generic manufacturing can readily select non-infringing solid forms
Where generics face higher barriers
- modified-release or reformulated versions protected by dissolution-related patents
- niche presentations with limited competitors and active manufacturing/process claims
- countries where patent linkage systems create additional procedural friction
What is the biosimilar risk profile for J01XE nitrofuran derivatives?
Featured snippet answer: Biosimilar risk does not apply. Nitrofuran derivatives in J01XE are small molecules, not biologics, and the relevant competition framework is generic small-molecule entry, not biosimilar pathways.
How do regulatory pathways (FDA ANDA vs other jurisdictions) interact with the patent estate in J01XE?
Featured snippet answer: In the US, the ANDA framework plus Orange Book listings determines the launch timeline more than new clinical exclusivities. In other jurisdictions, patent linkage and local regulatory exclusivities drive similar product-level timing constraints.
US pathway dynamics
- ANDAs for nitrofuran products face Orange Book listing impacts.
- 505(b)(2) applications may create different exclusivity outcomes if they rely on protected data, but for older nitrofuran derivatives, the dominant competitive structure is typically ANDA generics.
International dynamics
- Patent enforcement often remains the gating factor in jurisdictions without strong patent-linkage enforcement.
- In linkage regimes, unexpired formulation/process patents can delay market approval or trigger litigation.
How does nitrofuran derivatives’ patent landscape compare across dosage forms and strengths?
Featured snippet answer: Even within one molecule, the patent landscape can differ by dosage form and strength because different SKUs have distinct formulation patents and distinct Orange Book entries.
SKU-level differentiation that affects enforcement
- capsule vs tablet
- immediate-release vs modified release
- specific excipient systems
- stability engineering that can be claim-protected
- different strengths that map to different manufacturing lines
Strategic implications
- Market entry should be priced by SKU-level patent clearance, not by molecule-level clearance.
- Licensing strategies should align with specific dossier ownership and specific manufacturing/CMC capabilities that support non-infringing formulations.
Key Takeaways
- J01XE nitrofuran derivatives are dominated by older small molecules; primary composition-of-matter patents generally have expired in major markets, shifting the battlefield to formulation, solid-state, and manufacturing/process patents tied to specific marketed presentations.
- Market dynamics are SKU-driven: supply reliability, renal safety positioning, payer/formulary behavior, and product-level exclusivities often matter more than new clinical differentiation.
- Generic entry timing is governed by the Orange Book listing set per presentation and by the ability to design around formulation and solid-state claims.
- Litigation, where it occurs, typically resolves via settlement terms that control US launch dates or restrict certain product configurations rather than expanding broad new legal precedent.
FAQs
1) What types of patents most often remain active for nitrofuran derivatives after API expiry?
Formulation, solid-state (polymorph/hydrate), dissolution/particle engineering, and manufacturing-process patents for specific dosage forms and strengths.
2) Do Paragraph IV challenges meaningfully impact nitrofurantoin launch timing?
Yes when unexpired Orange Book-listed patents cover the reference presentation’s formulation or manufacturing; otherwise launch can proceed quickly.
3) Can a generic avoid infringement for nitrofuran derivatives by changing formulation or polymorph?
Often the design-around path depends on whether claims are limited to a specific solid state or manufacturing condition and whether the generic can consistently produce a non-infringing equivalent.
4) Are there biosimilar-like pathways for nitrofuran derivatives competition?
No. J01XE nitrofurans are small molecules; competition is generic ANDA (or local generics) driven.
5) What is the highest value due diligence step for a nitrofuran derivatives entry plan?
SKU-level patent and Orange Book clearance for the exact dosage form and strength, matched to the planned generic manufacturing route and chosen solid-state form.
References (APA)
- European Medicines Agency. (n.d.). ATC classification information and medicinal product listings. https://www.ema.europa.eu/
- FDA. (n.d.). Drugs@FDA database and product approvals. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
More… ↓
